NCT01494285View on ClinicalTrials.gov

Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

157

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Acne Vulgaris

Interventions

DRUG

ARK-E021 5%

Topically applied once daily at bedtime

DRUG

ARK-E021 10%

Topically applied once daily at bedtime

DRUG

Placebo

Topically applied once daily at bedtime

Trial Locations (3)

Unknown

HaEmek Medical Center, Afula

Meir Medical Center, Kfar Saba

Souraski Medical Center, Tel Aviv

All Listed Sponsors

collaborator

Vyne Therapeutics Inc.

INDUSTRY

lead

M. Arkin 1999 Ltd.

OTHER

NCT01494285 - Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients | Biotech Hunter | Biotech Hunter